Advertisement
Advertisement
U.S. Markets closed
Advertisement
Advertisement
Advertisement
Advertisement

Atea Pharmaceuticals, Inc. (AVIR)

NasdaqGS - NasdaqGS Real Time Price. Currency in USD
Add to watchlist
8.62-0.07 (-0.81%)
At close: 4:00PM EST
Advertisement
Full screen
Trade prices are not sourced from all markets
Gain actionable insight from technical analysis on financial instruments, to help optimize your trading strategies
Chart Events
Neutralpattern detected
Previous Close8.69
Open8.41
Bid8.43 x 1400
Ask8.70 x 3200
Day's Range8.13 - 8.67
52 Week Range7.37 - 94.17
Volume5,912,712
Avg. Volume5,019,011
Market Cap713.192M
Beta (5Y Monthly)N/A
PE Ratio (TTM)N/A
EPS (TTM)N/A
Earnings DateMar 30, 2021
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target Est51.00
  • Insider Monkey

    15 Pharmaceutical Stocks to Buy According to Peter Kolchinsky’s RA Capital

    In this piece, we will take a look at the top 15 pharmaceutical stocks to buy according to Peter Kolchinsky’s RA Capital. If you want to skip our introduction and take a look at the top five stocks in this list, head on over to 5 Pharmaceutical Stocks to Buy According to Peter Kolchinsky’s RA […]

  • GlobeNewswire

    Atea Pharmaceuticals to Present at the 4th Annual Evercore ISI HealthCONx Conference

    BOSTON, Nov. 22, 2021 (GLOBE NEWSWIRE) -- Atea Pharmaceuticals, Inc. (Nasdaq: AVIR) (“Atea”), a clinical-stage biopharmaceutical company, today announced that Jean-Pierre Sommadossi, PhD, Chief Executive Officer and Founder of Atea, will participate in a virtual fireside chat at the 4th Annual Evercore ISI HealthCONx Conference on Wednesday, December 1, 2021 at 3:05 p.m. ET. A live webcast of the presentation will be available here and on the Company’s website at www.ateapharma.com. A replay of

  • Zacks

    Atea (AVIR) Plunges on Termination of Collaboration With Roche

    Atea (AVIR) stock falls on termination of collaboration with Roche for the development of oral drug for the treatment of COVID-19.

Advertisement
Advertisement